Modified FOLFOX-6 Plus Bevacizumab May Be Effective for Liver-Only Metastases of Colorectal Cancer

Share this content:

the Cancer Therapy Advisor take:

According to a new study published in the journal Annals of Oncology, modified FOLFOX-6 (leucovorin, fluorouracil, oxaliplatin) plus bevacizumab caused a high rate of hepatectomy and allowed for a high number of initially unresectable cases of liver-only metastases of colon cancer to be resectable.

For the phase 2 clinical study, researchers enrolled 46 patientss with colorectal cancer with liver-only metastases. All patients received mFOLFOX-6 plus bevacizumab for six cycles, and following chemotherapy, a hepatectomy was performed if possible.

Results showed that 18 of 19 patients considered unresectable prior to therapy completed treatment and underwent hepatectomy and 6 of 26 patients considered initially unresectable underwent hepatectomy. In all, approximately 45% of the 45 patients included in the efficacy analysis were R0-resected.

The most common severe adverse events associated with chemotherapy were fatigue, leukopenia, and neutropenia, and the only adverse events associated with bevacizumab were hypertension and venous thromboembolism.

Of the 25 patients who underwent hepatectomy, two experienced grade 3 wound infections, one experienced blioma, one had delayed wound healing, and one had an intraperitoneal abscess intraoperatively or postoperatively.

In Metastatic Colorectal Cancer, Chemo-Induced Splenic Volume Elevation Linked With Major Postoperat
Modified FOLFOX-6 (leucovorin, fluorouracil, oxaliplatin) plus bevacizumab caused a high rate of hepatectomy.
In colorectal cancer patients with liver-only metastases, mFOLFOX6+ BV therapy yielded a high hepatectomy rate and a high percentage of initially unresectable and subsequently resectable cases. The chemotherapy associated adverse events and hepatectomy complications were both within acceptable ranges.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs